SION
Sionna Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth n/a ·
share flow n/a ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 2.95M | New | $30.89M | 0.1% | New | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 996.21K | New | $10.42M | 0.0% | New | 1 | SEC ↗ ×2 |
| 3 | Citadel Advisors ✦ | 326.50K | New | $3.42M | 0.0% | New | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 179.07K | New | $1.87M | 0.0% | New | 1 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 135.56K | New | $1.42M | 0.0% | New | 1 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 14.40K | New | $150,624 | 0.0% | New | 1 | SEC ↗ |
| 7 | Marshall Wace ✦ | 12.19K | New | $127,486 | 0.0% | New | 1 | SEC ↗ ×2 |
| 8 | Two Sigma Investments ✦ | 11.71K | New | $122,539 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Viking Global Investors | $30.89M | 0.1% |
| T. Rowe Price | $10.42M | 0.0% |
| Citadel Advisors | $3.42M | 0.0% |
| Millennium Management | $1.87M | 0.0% |
| Geode Capital Management | $1.42M | 0.0% |
| State Street Global Advisors | $150,624 | 0.0% |
| Marshall Wace | $127,486 | 0.0% |
| Two Sigma Investments | $122,539 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 121 holders, 43.94M shares, $1.73B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director, 10% owner · 3.42M sh · $21.58M
Director, 10% owner · 33.80K sh · $252,148
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
14.3% of class · View original SEC filing ↗